Your Search Results

Tackling calcified lesions with IVUS guidance and optimisation

20 May 2026 – From EuroPCR 2026

This session delves into the critical role of Intravascular Ultrasound (IVUS) in characterizing and managing calcified coronary lesions. Attendees can explore an imaging-guided approach to calcium treatment, including case presentations that demonstrate stent selection and procedural optimization. Emphasis is placed on applying imaging-based optimization metrics to...

Tackling calcified lesions with IVUS guidance and optimisation

When to best combine guided-directed medical therapy and devices at discharge of acute heart failure

20 May 2026 – From EuroPCR 2026

This session addresses the challenges and strategies in optimizing guided-directed medical therapy for acute heart failure patients, especially those intolerant to up-titration. It also covers the assessment and timing for cardiac resynchronisation therapy (CRT), highlighting the benefits of combining medical therapy and device implantation to improve...

When to best combine guided-directed medical therapy and devices at discharge of acute heart failure

Registries and trials in mitral TEER

20 May 2026 – From EuroPCR 2026

This comprehensive session reviews registries and clinical trials in mitral transcatheter edge-to-edge repair (TEER). It includes discussions on novel TEER systems, international consensus on PASCAL implants, anatomical predictors of procedural success, and long-term outcomes including ventricular and atrial remodeling after intervention, as well as emerging therapies...

Monotherapy vs. DAPT: striking the balance between ischemia and bleeding

20 May 2026 – From EuroPCR 2026

This session examines the balance between ischemic and bleeding risks by comparing monotherapy regimens and dual antiplatelet therapy (DAPT) following PCI. Key topics include clopidogrel versus aspirin monotherapy, aspirin discontinuation timing after ACS, and the impact of P2Y12 adherence on clinical outcomes in high-risk and oral...

5-year outcomes after transcatheter or surgical aortic valve replacement in low-risk patients with aortic stenosis (Evolut Low Risk)

01 Apr 2025

Yohei Ohno provides his takeaways from the results of the Evolut Low Risk trial which was presented by Michael J. Reardon during the ACC.25 in Chicago.